Clinical Trial Search

Primary: Overall Response Rate (ORR) Based on the Assessments by Investigator — 8.8; 36.8; 45.6 percentage of participants

Primary: Objective Overall Response Rate (ORR) in Relapsed or Refractory cHL. — 21.0; 28.6 percentage of participants

Primary: ORR Assess by IRC — 76.0 percentage

Primary: Objective Response Rate (ORR) Assessed According to the Revised International Working Group Response Criteria for Malignant Lymphoma in 2007(IWG 2007) by the Independent…

Primary: Complete Response (CR) Rate — 0; 36 percent of participants

Primary: Overall Response Rate — 20.0 percentage of participants

Primary: Determine the Overall Response Rate (RR) to Bendamustine HCL in Patients With Relapsed and Primary Refractory HL. — 56 percentage of evaluable participants

Primary: Objective Response — 3; 6; 3; 2 participants

Primary: Group 2, RRHL: Progression Free Survival (PFS) — 13.17 months

Primary: Objective Response Rate (ORR) — 25.00; 37.50; 75.00; 62.50 percentage of patients

Primary: Overall Response Rate (ORR) by BICR Based on IWG Criteria — 78.3; 64.2; 73.3 Percentage of participants

Primary: Determine the Overall Response Rate (ORR), Including Complete Responses (CR) and Partial Responses (PR) — 16.7 percentage of patients

Primary: Maximum Tolerated Dose of Brentuximab Vedotin That Can be Combined With Ifosfamide, Carboplatin, and Etoposide Chemotherapy — 1.5 mg/kg

Primary: Objective Response Rate (ORR) — 50 percentage of participants

Primary: Overall Response — 3 participants

Primary: Progression-free Survival at 1 Year — 33.3 proportion of progression-free pts

Primary: Overall Response Rate (ORR) — 0.05 Proportion of participants

Primary: Assess Number of Patients Who Achieve Confirmed and Unconfirmed Complete Response (CR) or Partial Response (PR) — 0; 1; 0; 0 participants

Primary: Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants

Primary: Objective Response Rate (ORR) as Assessed by the Investigator Based on Cheson Response Criteria — 5; 30; 71; 14 Participants

Primary: Number of Patients Reporting Dose-Limiting Toxicity (DLT) (Phase I) — 1; 2; 3; 0 Participants

Primary: Incidence of Dose-limiting Toxicity (DLT), Phase I Patients Only — 1; 0; 3; 0 Participants

Primary: Number of Participants With Overall Response (OR) — 15; 4 participants

Primary: Number of Participants With Adverse Events (AEs) — 6; 55; 30; 5 Participants

Primary: Response Rate After 2 Courses of Therapy — 4 participants

Primary: Part A (Dose Escalation): Number of Participants With Adverse Events (AEs) — 1; 1; 1; 1 Participants

Primary: Progression-Free Survival According to the Cheson Criteria by Kaplan-Meier Analysis Following Orally Administered PLX3397 in Adults With Relapsed or Refractory Hodgkin…

Primary: Number of Participants With Treatment-emergent Adverse Events as a Measure of Safety and Tolerability of Nivolumab as Maintenance Therapy — 33 Participants

Primary: Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, Predose — NA; NA; NA; NA ng/mL

Primary: Adverse Events in Terms of Dose-limiting Toxicity (DLT) and MTD of Bendamustine Hydrochloride (Phase I) — 0; 0; 0; 0 number of patients